[IE-02] International Education Course 02「JNNP: Improving Outcomes in Patients with Neurological Disorders」

[IE-02-1] Recent therapeutic Advances in Neuromuscular Diseases

Aisling S. Carr^1,2 (1.Centre for neuromuscular diseases, National Hospital for Neurology and Neurosurgery, 2.Department of Neuromuscular diseases, Institute of Neurology UCL)

• Consultant Neurologist
• Chair Neuromuscular Advisory Group ABN
• Associate Editor Neuromuscular Disease, JNNP
Research: Inflammatory neuropathies, biomarker development, neurological toxicity related to immune therapies
Research:
- Dr Carr was appointed as a consultant neurologist in the centre for Neuromuscular diseases, NHNN in 2016. She completed undergraduate medical education in Trinity College Dublin and Université François Rabelais, France (honors). With post-graduate training in medicine and Neurology in the Northern Ireland deanery. Her subspeciality expertise in neuromuscular diseases was developed through a Masters in myologie, Universite de Pierre et Marie Curie Paris, PhD in myasthenia epidemiology between Queen’s university Belfast and Oxford and a clinical fellowship in Peripheral Nerve in the National Hospital for Neurology and Neurosurgery, London. She is a full time clinical neurologist with a subspecialty interest in inflammatory peripheral nerve and runs a pan-London immune checkpoint inhibitor neurotoxicity service and is the neurologist on the national HLH MST run through UCLH. Her particular clinical research interest is inflammatory neuropathy, biomarker development and understanding the toxicities of immune therapies. She is UCLH PI for ADHERE (phase 2/3 randomised control trial of efgartigimod in CIDP) and UK CI/ UCLH PI for ARDA (phase 2/3 randomised control trial for C2 complement inhibitor in MMN).